MOG and colitis: CARs have been used to redirect Treg to target 2,4,6-trinitrophenol (TNP), carcinoembryogenic antigen (CEA), factor VIII (FVIII), myelin oligodendrocyte glycoprotein (MOG), human leukocyte antigen A2 (HLA-A2), and CD19 in preclinical models of colitis, hemophilia, multiple sclerosis, and transplantation, respectively (224, 227).